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Abstract
Dose of Trp53, the main keeper of genome stability, influences tumorigenesis; however, the causes underlying and
driving tumorigenesis over time by the loss of a single p53 allele are still poorly characterized. Here, we found that
single p53 allele loss specifically impacted the oxidative, DNA damage and inflammatory status of hematopoietic
lineages. In particular, single Trp53 allele loss in mice triggered oxidative stress in peripheral blood granulocytes and
spleenocytes, whereas lack of two Trp53 alleles produced enhanced oxidative stress in thymus cells, resulting in a
higher incidence of lymphomas in the Trp53 knockout (KO) mice compared with hemizygous (HEM). In addition, single
or complete loss of Trp53 alleles, as well as p53 downregulation, led to a differential increase in basal, LPS- and UVB-
induced expression of a plethora of pro-inflammatory cytokine, such as interleukin-12 (Il-12a), TNFα (Tnfa) and
interleukin (Il-23a) in bone marrow-derived macrophage cells (BMDMs) compared to WT cells. Interestingly, p53-
dependent increased inflammatory gene expression correlated with deregulated expression of the NF-κB pathway
inhibitor IκBα. Chromatin immunoprecipitation data revealed decreased p65 binding to Nfkbia in the absence of p53
and p53 binding to Nfkbia promoter, uncovering a novel crosstalk mechanism between p53 and NF-κB transcription
factors. Overall, our data suggest that single Trp53 allele loss can drive a sustained inflammatory, DNA damage and
oxidative stress response that, over time, facilitate and support carcinogenesis.
Introduction
The tumor suppressor TP53 (Tumor Protein P53) is
among the most frequently mutated genes in a plethora of
tumors, with more than 25,000 mutations registered in
the International Agency for Research on Cancer. This
guardian of the genome plays an essential role in the
response to DNA damage and cellular stress induced by
external and internal insults, which in turn trigger p53
expression and activation1,2.
According to its functional relevance, p53 levels are
regulated by multiple transcriptional, translational, and
post-translational mechanisms. In non-stressed cells,
p53 levels are kept relatively low by means of MDM2
activity (Mouse Double Minute 2), which ubiquitinates
p53 leading to its proteasomal degradation. In response to
cellular stressors (DNA damage, hypoxia or oxidative
metabolism, among others), interaction between p53 and
MDM2 is disrupted thus resulting in a quick increase in
p53 stabilization and activity associated with additional
post-transcriptional modifications such as sumoylation,
phosphorylation, acetylation and glycosylation1,2. In this
manner, p53 accumulates and translocates to the nucleus,
where it regulates the expression of genes that control
numerous cellular functions, such as cell cycle, apoptosis,
differentiation, senescence, DNA repair, and oxidative
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stress3–5. In fact, p53 tumor suppressor activity mainly
relies in its function as upstream regulator of inflamma-
tory gene transcription and oncogene-induced cell
death6–8. Consequently, p53 knockout (KO) mice
(Trp53−/−) show a higher expression of pro-inflammatory
cytokines than wild-type (WT) mice9–11, and are prone to
chronic inflammation12 as well autoimmune diseases13,14.
Moreover, about 25% of p53 KO mice died owing to
unresolved spontaneous inflammatory responses15.
Supporting the importance of p53 levels regulation,
single loss or inactivating mutations of a Trp53 allele are
sufficient to induce tumorigenesis, as it is observed in
patients of Li-Fraumeni syndrome that carry a germinal
mutation of p53 gene in about 70% of cases16. Impor-
tantly, the frequency and spectrum of tumors arising in
Trp53 hemizygous (HEM) and homozygous KO mice are
radically different, as well as their life expectancy15,17–24.
The mechanisms underlying these differences remain
largely undefined. In this sense, whereas tumor develop-
ment in HEM mice and Li-Fraumeni syndrome patients,
has been associated with a loss of hemizygosity or to a
dominant-negative effect of mutated p5323,25–30, around
50% of tumors in HEM mice retain a copy of the WT
allele20,23,25, suggesting that reduced dosage of p53 is
sufficient for cancer development.
To gain insight into the mechanisms behind Trp53
dosage loss influence in tumor spectrum, we have ana-
lyzed the early and late tumor phenotypes arising in p53
HEM and KO mice. Moreover, we have determined the
amount of oxidative stress, DNA damage and inflamma-
tion, which are relevant hallmarks on the onset and evo-
lution of carcinogenesis, under conditions of single and
complete Trp53 allele loss. Our results show that HEM
and KO mice and cells display specific alterations in
oxidative stress, DNA damage and expression of key pro-
inflammatory cytokines that may contribute to the dif-
ferent tumor phenotypes observed. Furthermore, we
demonstrate that p53 affects the expression of the NF-κB
inhibitor IκBα, leading to altered NF-κB-regulated gene
expression by promoting recruitment of p65 into Nfkbia
promoter. These results reveal a novel mechanism of
crosstalk between p53 and NF-κB transcription factors
with impact on inflammation and cancer.
Materials and methods
Mice
The Trp53tm1Tyj mice19 were backcrossed to C57BL/
6N background. P53 WT, p53 hemizygous (Trp53+/−,
HEM) and p53 knockout (Trp53−/−, KO) mice were
housed and bred in the Parc Científic of Barcelona and the
Bellvitge’s animal facilities of the University of Barcelona.
All mice procedures and methods were approved by the
Ethics Committee for Animal Experimentation of the
Catalan Government (# 7067 & 9119), and were
performed in accordance with the relevant guidelines and
regulations. Survival and spontaneous tumor develop-
ment were monitored for up to 3 years. Mice were closely
monitored and euthanized when they reached humane
endpoint and autopsies were performed on these mice
and the rest of the mice when they reached the
36 months. Tissues were fixed in 10% neutral-buffered
formalin solution, processed for paraffin embedding and
H&E staining and examined by a pathologist. Tumori-
genic and leukocyte analysis were undertaken in 4-
month-old male and female mice. A method of rando-
mization was not used to determine how animals were
allocated to each group. Pathologist was blinded to the
mice genotype. Primers used to determine Trp53 mouse
genotypes by PCR were as follows: 5′TGGTTTGTG
CGTCTTAGAGACAGT, 5′AAGGATAGGTCGGCGGT
TCAT and CCAGCTCATTCCTCCCACTCA.
Tissues, cell cultures, and treatment
Tissues were collected from WT, HEM, and KO mice
and primary bone-marrow-derived macrophages
(BMDMs) were prepared from bone marrow cells of the
hind limbs of mice, as described31. Macrophages were
obtained growing cells in Dulbecco’s Modified Eagle’s
Medium supplemented with 20% FBS and 30% L-cell
(medium obtained from the supernatant of L929 cells
used as source of M-CSF, Macrophage-Colony Stimulat-
ing Factor) for up to 7 days. Then, cells were scrapped and
seeded in plates for experiments. Cells were treated with
100 ng/ml LPS (Lipopolysaccharide) [Sigma] and 1 ng/ml
IFNγ [ImmunoTools] for the indicated times. Cells were
exposed to ultraviolet B (UVB) irradiation once medium
was removed using a UV lamp [UVP Inc.] at the distance
of 50 cm, and then fresh medium was added. A Radio-
meter with UVX-31 sensors was used [UVP Inc] to
monitor UVB doses. The doses were 50 and 100 J/m2
for UVB.
RT-qPCR analysis
Total RNA isolated from cells [NucleoSpin RNA
extraction kit, Macherey-Nagel] was used for cDNA
synthesis [GeneAmp RNA PCR kit, Applied Biosystems].
Quantitative PCR amplification reactions were performed
in the 7500 Fast Real-Time PCR System [Applied Bio-
systems] using TaqMan Gene Expression Master Mix.
Values were normalized to Sdha. The following TaqMan
assays [Applied Biosystems] were used to quantify mRNA
expression of mouse Sdha (Mm01352366_m1), Il-1β
(Mm00434228_m1), Il-1α (Mm00439620_m1), Mpo
(Mm01298424_m1) and Tnfα (Mm00443258_m1). The
following primers were used to quantify mRNA expres-
sion: Il-6 (Forward (F), AGTTGCCTTCTTGGGACTGA;
Reverse (R), TCCACGATTTCCCAGAGAAC), IL-12a (F,
GTACCAGACAGAGTTCCAGG; R, CGCAGAGTCTC
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GCCATTATG), IL-18 (F, CTACCCTCTCCTGTAAG
AAC; R, CTTGTTGTGTCCTGGAACAC), IL-23a (F,
CAAGGACTCAAGGACAACAG; R, GGTGTGAAGTT
GCTCCATG), NFKbia (F, AACCTGCAGCAGACTCCA
CT; R, GACACGTGTGGCCATTGTAG), Trp53 (F, CAC
AACTGCACAGGGCAC; R, CATGGAGGAGTCACAG
TCGG).
Protein extracts and western blot analysis
Whole-cell extracts for western blotting were obtained
in ice-cold lysis buffer containing 1% Nonidet P-40, 1%
deoxycolate, 0.1% SDS, 50 mmol/L HEPES pH 7.5 and
150mmol/L NaCl together with protease and phospha-
tase inhibitors (10 µg/ml aprotinin, 10 µg/ml leupeptin,
86 µg/ml iodoacetamide, 1 mM PMSF and 1mM
Na3VO4). For soluble and chromatin separations, cells
were lysed in 1mM EDTA, 0.1 mM Na-orthovanadate
(Na3VO4), 0.5% Triton X-100, 20 mM β-glycerol-phos-
phate, 0.2 mM PMSF, protease inhibitor cocktail, in PBS
for 20min on ice and centrifuged at 13,000 rpm. Super-
natants were recovered as the soluble fraction, and the
pellets were lysed in Laemmli buffer (1× SDS-PAGE
buffer plus β-mercaptoethanol [Sigma, Ref. M-3148]). For
the analysis of proteins in cell supernatants, media of
treated cells were collected, and liquids were evaporated
using Speed Vaccum concentrator [Thermo Scientific].
Samples were boiled in Laemmli buffer and separated on
SDS-PAGE. Western blot was performed as previously
described32. Primary antibodies used throughout this
study include, phospho-ATM (s1981) [Millipore, 05-740],
ATM [Santa Cruz, sc-135663], β-actin [GenScript,
A00702], phospho-Chk1 [Cell Signaling, #2348], Chk1
[Cell Signaling, #2360], COX2 [Cayman Chemical,
160116], phospho-Histone H2A.X (Ser 139) [Cell signal-
ing, #2577S], H3 [Abcam, ab1791], IL-1β [Pierce,
MM425B], IκBα [Santa Cruz, sc-371], IκBα phosphory-
lated in Ser32/36 [Cell Signaling, #9246], iNOS [Santa
Cruz, sc-650], p53 [Cell Signaling, #2524] and tubulin
[Sigma Aldrich, T6074]. Horseradish peroxidase-
conjugated goat anti-rabbit or goat anti-mouse anti-
bodies (1:10,000) [BioRad] were used as secondary
antibodies. Detection was performed with enhanced
chemiluminescence [Biological Industries] and auto-
radiography films [GE Healthcare]. Band quantification
was performed using Adobe Photoshop CC 2015.
Immunofluorescence analysis
Cells were fixed with 4% paraformaldehyde in PBS and
permeabilized with 0.1% Triton X-100 in PBS. After blocking
(20% FBS in PBS), samples were incubated with rabbit anti-
p65 [Cell Signaling]. Goat anti-rabbit IgG coupled to Alexa
Fluor 555 or 488 (1:500) was used as secondary antibody
[Life Technologies]. Nuclei were stained with DAPI [Sigma].
Slides were mounted in ProLong Gold Anti-Fade reagent
[Life Technologies]. Images of LPS-treated BMDMs were
captured in an SP5 upright confocal microscope (Leica).
Images of UVB-treated BMDMs were captured in an Eclipse
E-800 Nikon fluorescence microscope.
Myeloperoxidase activity
The activity of myeloperoxidase (MPO) was determined
biochemically, as described previously15. First, the ery-
throcytes were lysed [Lysis buffer BD FACS, Becton,
Dickinson and Company]. To release MPO from cells, the
samples were homogenized in 0.5% hexadecyl-
trimethylammonium bromide in 50mM potassium
phosphate buffer, pH 6.0. After that, samples were sub-
jected to three cycles of sonication, freezing and thawing.
Then, they were centrifuged for 30min at 14,000 rpm at
4 °C. The supernatants were mix with 0.334 mg/mL O-
dianisidine dihydrochloride and 0.005% H2O2 in 50mM
potassium phosphate buffer, pH 6.0. In this enzymatic
reaction H2O2 acts as substrate and O-dianisidine dihy-
drochloride as colorimetric reactive. MPO activity was
measured spectrophotometrically over a 10min period at
405 nm with a programmable microplate reader [Mole-
cular Devices, Menlo Park, CA]. Data were analyzed with
GraphPad Prism6 software.
Flow cytometry analysis
Cells from the blood, spleen and thymus of 4-month-
old Trp53−/−, Trp53−/+, and wt mice were stained fol-
lowing standard protocols with the following antibodies to
lymphocyte cell surface markers: FITC anti-mouse CD3e
[ImmunoTools, clone 145-2C11], PE anti-mouse CD4
[Immunotools, clone YTS 191.1.2], APC anti-mouse CD8
[Immunotools, clone YTS 169.4], FITC anti-mouse α/
βTCR [Immunotools, clone H57-597], PE anti-mouse
γδTCR [Immunotools, clone GL-3], FITC anti-mouse
CD5 (BD Pharmigen, 553020) and PE anti-mouse CD19
[ImmunoTools, clone PeCa1]. Forward scatter versus side
scatter plot was used to gate lymphocyte, monocyte, and
granulocyte blood cells. Analysis were performed with a
FACSCanto flow cytometer [Becton Dickinson].
Oxidative stress analysis
Reactive oxygen species (ROS) levels were determined
by incubating mouse blood 30min at 37 °C with 5 μM
CellROX Deep Red Reagent [Life Technologies], which
emits fluorescence upon oxidation by ROS. After the
staining, Red blood cells Ammonium Chloride lysis buffer
was used (155 mM NH4Cl, 1 mM KHCO3, 0.1 mM EDTA
in water, pH7.2). Fluorescence was measured with a
FACSCanto flow cytometry [Becton Dickinson].
Chromatin immunoprecipitation (ChIP)
Cells were crosslinked 10min with 1% formaldehyde,
lysed and sonicated. Chromatin fractions were incubated
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for 16 h with anti-p53 [abcam ab1101], anti-p65 [Abcam
ab16502], mouse IgG [Sigma I5006] or rabbit IgG [Sigma
I5381] antibodies in RIPA buffer and then precipitated
with protein A/G-sepharose [GE Healthcare, Refs. 17-
0618-01 and 17-0780-01]. Crosslinkage was reversed and
DNA was purified. Then, qPCR was performed as
explained above. Results were normalized to Input and Ig
values. The following primers were used: p53 motif in
Nfkbia promoter (F, GAGGCTAGCCACCACAGAAG; R,
CTGGCTTGGGTCAATTGTTT), p53 motif in Mdm2
gene (F, GCCGAGTTGACTCAGCTCTT; R, TAAAC
GCTGGCAGGGGATTT), p65 motif in Nfkbia promoter
(R, AGGCTGCAGGGAAGTACCTA; F, TAAACGCTG
GCAGGGGATTT).
Knockdown assays
Lentiviral particles containing two different MISSION
shRNAs for mouse p53 [Sigma, TRCN0000310844 and
TRCN0000331409] and non-target shRNA control
[Sigma, SHC016] were obtained by transfection of plas-
mids into HEK293T cells, following standard procedures.
One day after transfection, media was refreshed. Virus
was collected 24 h later and then concentrated using
Ultracentrifuge Optima™ XPN-100-IVD (Biosafe) [Beck-
man Coulter]. BMDMs were infected and after 24 h
selected with puromycin (0.25 μg/ml) for 3 days before
stimuli treatment.
Statistical analysis
Statistical parameters, including number of events
quantified, standard error of the mean (SEM), and sta-
tistical significance are reported in the figures and in the
figure legends. Statistical analysis has been performed
using GraphPad Prism6TM Software and p < 0.05 is
considered significant. Two-sided Student’s t test was
used to compare differences between genotypes or treat-
ment conditions. Outliers were identified with Outlayer
ROUT method (Q= 1%) using GraphPad Prism6TM.
Results
Specific pro-tumorigenic effects and hematopoietic
alterations after Trp53 single and double allele loss
We first analyzed the tumor incidence and spectrum and
hematopoiesis of our p53-deficient mice (HEM and KO)
maintained in a C57BL/6N background. Pathological analysis
of mice at 4 months of age demonstrated that most p53 KOs
(about 70%) developed early lymphomas in contrast with
only few HEM animals (about 10%) developing adenomas
and teratomas, and WT animals (about 5%) that developed
lymphomas (Fig. 1A). At this relatively early age, all animals
bared only one tumor type, matching percentages of tumor
incidence with those of tumor spectrum. In agreement with
this early phenotype, at the time of death, single and double
p53 allele loss led to p53 dose-dependent decrease in survival
(Fig. S1A), whereas tumor incidence is increased (Fig. S1B),
and to a differential tumor spectrum (Fig. S1C), as described
previously15,17–24. Notably, tumor spectrum at 4 months
anticipated the tumor spectrum at time of death, showing a
higher frequency of lymphomas in p53 KO than in HEM and
WT mice. The early low lymphoma frequency seen in WT
animals at 4 months of age as well as the predominance of
lymphoma in those WT animals bearing tumors at time of
death, are consistent with the fact that lymphoma are the
most common tumors in many strains of mice, up to
20–40% in C57BL/6 strains33, including young individuals.
Because lymphomas are the most frequent type of cancer in
p53 KO mice, we studied the hematopoietic component. By
flow cytometry analysis of peripheral blood, in 4-month-old
mice we found comparable percentages of lymphocytes,
monocytes and granulocytes in all three genotypes (Fig. 1B)
but specific alterations in the lymphocyte subpopulations in
the KOs (Fig. 1C). In particular, p53 KO mice showed a
significant decrease in the percentage of total T cells (CD3+;
CD5+ CD19−), mainly TCRαβ+ and T helper cells (CD3+
CD4+), and increased percentage of the T cytotoxic cells
(CD3+ CD8+). Moreover, p53 KO mice showed increased
percentage of NK cells (CD5-CD19−). No significant
alterations in any of the analyzed hematopoietic cell popu-
lations were observed in WT and p53 HEM mice (Fig. 1C).
Furthermore, the analysis of thymic populations showed
obvious defects on thymocyte development only in the p53
KOs characterized by an increase in CD3+, single CD8+ and
double CD4+ CD8+ subsets, but reduced numbers of single
CD4+ cells and the CD4/CD8 ratio (Fig. S1D), which is in
agreement with the changes in T lymphocytes observed in
peripheral blood (Fig. 1C).
Together these results indicated that a single Trp53
allele is sufficient to prevent early tumorigenesis that
primarily arises in hematopoietic double deficient
Trp53 cells. However, p53 HEM mice still developed a
reduced number of solid tumors including adenomas
and teratomas.
Loss of one Trp53 allele leads to increased oxidative status
in peripheral blood granulocytes and bone marrow-
derived macrophages (BMDMs)
Reactive Oxidative Species (ROS) are among the best-
known triggers of carcinogenesis34 and multiple evidences
support the important role of p53 in regulating intracel-
lular redox homeostasis34,35. Thus, we speculated that
differences in the oxidative stress might contribute to the
differential tumorigenic phenotype of p53 HEM and KO
mice. We used CellROX and flow cytometry to quantify
the impact of p53 levels in ROS production from the
major leukocyte subsets (lymphocytes, monocytes and
granulocytes) (Fig. S2A, B). Analysis of tumor-free
4-month-old p53 WT, HEM and KO mice indicated
that levels of ROS were higher in p53 KO granulocyte and
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lymphocytes than in the corresponding WT cell subsets.
ROS levels were also elevated in p53 HEM cells, although
significant statistical differences were only detected in the
granulocyte component (Figs. 2A, S2B). To further
investigate this phenotype, we analyzed the enzymatic
activity of the MPO enzyme, a key player in the genera-
tion of ROS36, in peripheral blood leukocytes, spleen and
thymus. MPO was mainly expressed in hematopoietic
stem cells (HSCs), myeloid and granulocytic progenitors,
granulocytes and natural killer (NK) cells (Fig. S2C). Our
results demonstrated that p53 KO imposed a significant
increase in MPO activity in circulating leukocytes, spleen
and thymus cell populations, whereas loss of a single
Trp53 allele similarly affected circulating leukocytes and
the spleen cells but had a minor effect on the thymus
component (Fig. 2C). Analysis of Mpo mRNA expression
Fig. 1 Tumor spectrum and lymphocyte subsets in p53 hemizygous and p53 knockout mice. A Percentage of tumor incidence and spectrum
in 4-month-old WT, p53 hemizygous (HEM) and knockout (KO) mice. B Percentage of lymphocyte, monocyte, and granulocyte populations in
bloodstream of 4-month-old WT, HEM and KO mice measured by flow cytometry analysis. C Percentage of lymphocyte populations in bloodstream of
4-month-old WT, HEM and KO mice measured by flow cytometry analysis. In A, B and C, at least 20 mice per genotype were analyzed. In B and C, bars
represent mean values ± SEM. Significant differences and p values were derived from an unpaired t-test, two-tailed. WT vs HEM or KO: **p value <
0.005, *p value < 0.05. HEM vs KO: ###p value < 0.0005, ##p value < 0.005. Identified outliers were represented as gray dots.
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in p53 WT, HEM and KO BMDMs, spleen and thymus
cells closely correlated with MPO activity (Fig. 2D),
indicating that MPO regulation can take place at least
partially at the transcriptional level.
Inducible nitric oxide synthase (iNOS) and cycloox-
ygenase 2 (COX2) contribute to the generation of the
nitric oxide (NO) and superoxide (O2−) reactive species,
respectively, and are key pro-oxidant enzymes37. Western
blot analysis of BMDMs indicated that upregulation of
COX2 after treatment with LPS plus IFNγ was higher in
the absence of one Trp53 allele compared to WT or p53
KO cells (Fig. 2E). In a similar way, LPS alone induced
higher expression of iNOS in p53 HEM than KO or wt
BMDM, whereas stimulation with combined LPS and
IFNγ induced higher levels than wt in both p53 HEM and
KO BMDM. However, iNOS and COX2 activation fol-
lowing single or compound LPS and IFNγ treatment was
determined at a single time point, thus results should not
be considered as absolute as they integrate possible dif-
ferences in activation kinetics between p53 genotypes.
Overall, reduction of p53 levels affects oxidative stress
in different hematopoietic cell populations and tissues.
The loss of one allele is sufficient to increase oxidative
stress in granulocytes, BMDMs and spleen cells. However,
single allele of Trp53 precludes enhanced ROS production
imposed by complete p53 deficiency in lymphocytes and
thymus cells, which is in agreement with the higher
incidence of lymphomas in p53 KO mice.
Loss of one Trp53 allele enhances the expression of pro-
inflammatory cytokines in untreated and stress-treated
BMDMs
Oxidative stress response is frequently associated with the
pro-inflammatory response38–41 and p53 deficiency has
been linked with increased expression of pro-inflammatory
cytokines9–11. To determine whether single Trp53 allele loss
influenced the inflammatory response, we performed RT-
qPCR analysis of several key pro-inflammatory cytokines in
BMDMs. As expected, p53 KO cells did not express Trp53
mRNA and p53 HEM cells expressed approximately 50%
compared with WT cells, and this proportion was main-
tained after LPS treatment (Fig. 3A). Interestingly, p53 KO
and HEM BMDMs showed increased mRNA expression of
the cytokines IL-1β, IL-6, IL-12α, IL-18, IL-23α, and TNFα
in the absence of LPS stimulation. Of note, LPS-induced
mRNA expression of the studied cytokines was higher in
p53 HEM and KO BMDMs than in WT cells. Interestingly,
Il-23α expression was significantly higher in the HEM than
in KO cells whereas the expression of Il-1α and Il-18 was
higher in KO than HEM cells (Fig. 3A). Consistent with the
Il-1βmRNA expression data, protein levels of IL-1β (31 kDa
pro-form and 17 kDa active form) were increased in LPS-
treated p53 HEM and KO BMDMs compared with the WT
(Fig. 3B). The active form was higher in KO than in HEM
cells, suggesting a higher activation of the inflammasome42
by p53 dosage.
To analyze whether p53 levels affected the immune
response to other stress stimulus, we checked the
response to UVB radiation. Importantly, UVB treatment
induced a dose-dependent stabilization of p53 protein, as
described previously43–46, which was significantly lower in
HEM cells than in WT (Fig. 3C). Similarly to LPS
response, UVB-induced expression of the main pro-
inflammatory cytokines IL-1β, IL-6, and TNFα was higher
in p53 HEM and KO BMDMs compared to WT (Fig. 3D).
Overall, these results indicate that the loss of a single
Trp53 allele is sufficient to trigger a pro-inflammatory
response in homeostasis as well as increase the stress-
induced expression of several key pro-inflammatory
cytokines. Furthermore, Trp53 allele loss could affect
kinetics of expression, as previously mentioned.
Increased nuclear p65/NF-κB localization in stress-treated
BMDM cells by the loss of a single Trp53 allele
Induced expression of pro-inflammatory cytokines lays
mainly downstream of NF-κB signaling47. Thus, we next
studied whether increased cytokine expression in p53
HEM and KO cells was due to increased or sustained
p65/NF-κB signaling. By immunofluorescence analysis
we failed to detect any nuclear (active) p65/NF-κB in
(see figure on previous page)
Fig. 2 Loss of one Trp53 allele leads to an increased oxidative status in immune cells and tissues. A Representative histograms showing
oxidative stress analysis by flow cytometry using CellROX reagent in the major subsets of blood leukocyte samples: lymphocytes, monocytes, and
granulocytes from 4-month-old p53 WT, HEM, and KO mice. B Quantification of CellROX by flow cytometry analysis. Five mice per genotype were
analyzed. C Myeloperoxidase (MPO) activity analysis in peripheral blood leukocytes, spleen and thymus samples from 4-month-old WT, HEM, and KO
mice. At least five mice per genotype were analyzed. Graphs represent the absorbance (ABS) of O-dianisidine dihydrochloride, which reflect the
amount of H2O2 processed by MPO. D Relative mRNA expression of the Myeloperoxidase (Mpo) gene in bone marrow-derived macrophages
(BMDMs), spleen and thymus from 4-month-old WT, HEM, and KO mice. For BMDM quantification, biological replicates were performed in five
independent experiments. For hematopoietic tissues quantification, at least eight mice per genotype were analyzed. E Protein expression of
ciclooxygenase 2 (COX2) and inducible nitric oxide synthase (iNOS) in BMDMs of the indicated genotypes treated for 24 h with LPS (100 ng/ml) and/
or IFNγ (1 ng/ml). Relative expression values were referred to β-actin expression. Representative image of a western blot analysis from two
independent experiments is shown. In B and D, bars represent mean values ± SEM. AU arbitrary units. Significant differences and p values were
derived from an unpaired t-test, two-tailed. In C, linear regression analyses were performed. WT vs HEM or KO: ****p value < 0.0001, ***p value <
0.0005, **p value < 0.005, *p value < 0.05, n.s. non-significant. HEM vs KO: ##p value < 0.005, #p value < 0.05.
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untreated cells of either genotype. Nevertheless, nuclear
p65/NF-κB translocation after LPS (Fig. 4A, B) or UVB
(Fig. S3A, B) treatment was significantly higher in p53
HEM and KO cells than in WT BMDMs. These results
indicated that the loss of Trp53 alleles impose a dose-
dependent effect on LPS- and UVB-induced activation
of key pro-inflammatory cytokines, associated with
increased p65/NF-κB signaling.
Fig. 3 Loss of one Trp53 allele leads to an increased pro-inflammatory cytokine expression in untreated and LPS and UVB-treated BMDM
cells. A Relative mRNA expression of the indicated genes in BMDMs from p53 WT, HEM, and KO mice untreated (control) and treated (LPS, 100 ng/ml,
4 h). Biological replicates were quantified in four independent experiments. B Expression of IL-1β pro-form (31 kDa) and active isoform (17 kDa) in total
cell extracts and supernatants of BMDMs from WT, HEM, and KO mice untreated (control) and treated (LPS, 100 ng/ml, 4 h). Relative expression values
in cell extracts were referred to β-actin expression. Representative image of a western blot analysis from at least two independent experiments is
shown. C Expression of p53 in BMDMs from WT, HEM, and KO mice untreated and irradiated with UVB (50 or 100 J/m2, 24 h). Relative expression values
were referred to β-actin expression. Representative image of a western blot analysis from two independent experiments is shown. D Relative mRNA
expression of the indicated pro-inflammatory cytokine genes. BMDMs from WT, HEM, and KO mice were untreated and treated with UVB (50 J/m2, 1 h).
Biological replicates in three independent experiments were analyzed. In A and D, bars represent mean values ± SEM. AU arbitrary units. Significant
differences and p values were derived from an unpaired t-test, two-tailed. WT vs HEM or KO: ****p value < 0.0001, ***p value < 0.0005, **p value < 0.005,
*p value < 0.05. HEM vs KO: ####p value < 0.0001, ##p value < 0.005, #p value < 0.05.
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Fig. 4 Loss of one Trp53 allele leads to increased p65/NF-κB nuclear localization and increased DNA damage response in LPS- and UVB-
treated BMDM cells. A Representative p65 immunofluorescence images of untreated (Control) and treated (LPS, 100 ng/ml, 15 min) BMDMs from
p53 WT, HEM and KO mice. B Quantification of the percentage (%) of cells positive for nuclear p65 localization in control and LPS (100 ng/ml, 15 min)-
treated BMDMs. A minimum of 500 cells per genotype was counted in two independent experiments. C Expression of DNA damage response
proteins in BMDMs treated with LPS (100 ng/ml) or UVB (50 J/m2 and 100 J/m2) for 4 or 24 h (h) from p53 WT, HEM, and KO mice. Representative
images of western blot analysis from two independent experiments are shown. n.s. non-specific band. D Expression of P-H2A.X in BMDMs treated
with UVB (50 J/m2 and 100 J/m2) for 4 or 24 h (h) from p53 WT, HEM, and KO mice. Representative images of western blot analysis from two
independent experiments are shown. E Quantification of western blot analysis (in D) of UVB-treated WT, HEM, and KO BMDMs. Means of two
independent experiments are shown. In A, scale bars are 25 μm. In B, bars represent mean values ± SEM. AU arbitrary units. Significant differences and
p values derived from an unpaired t-test, two-tailed. WT vs HEM or KO: ***p value < 0.0005, *p value < 0.05.
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Increased DNA damage in stress-treated BMDM cells by
the loss of a single Trp53 allele
As inflammation and pro-inflammatory response, DNA
damage and the DNA damage response were specifically
affected by the single and double loss of Trp53 alleles
(Figs. 4C, S4A). In particular, the DNA repair signaling
pathways to single-strand breaks (SSB, assessed by levels
and kinetics of P-Chk1) as well as double-strand breaks
(DSB, assessed by levels and kinetics of P-ATM) were
induced in a particular way by the loss of single and
double Trp53 allele compared to WT after LPS and UVB
threats (Figs. 4C and S4A). Higher amount of the P-H2A.
X, mark of DNA strand breaks48, accumulated in KO and
HEM compared to WT cells after UVB stimuli. Intrigu-
ingly, P-H2AX levels were slightly stronger and lasted
longer in UVB-treated cells at low (50 J/m2) than at high
(100 J/m2) doses (Fig. 4C–E). This fact could be in part
related to a higher rate of cell death at high than low UVB
doses. Also, it cannot be ruled out a relatively highest peak
of DNA damage in the high dose UVB-treated cells
between 1 and 4 h. On the other hand, KO cells but not
HEM cells did show high levels of DNA damage than
WT cells at 24 h after LPS treatment. Consistently, sta-
bilization of p53 protein, which followed similar kinetic
patterns in WT and HEM cells, peaks at 24 h after LPS
and 4 h after UVB (Figs. 4C, S4A). The earlier and
stronger DNA damage response upon UVB radiation
compared to LPS treatment would be related to the direct
DNA damaging activity of UVB in contrast with the
indirect oxidative DNA damage triggered by LPS as
consequence of the production of ROS, among other
reactive species. Overall, these results indicate that single
Trp53 allele loss results in an increase of DNA damage
upon genotoxic stimuli, compromising thus genomic
stability.
Increased NF-κB signaling and delayed IκBα re-synthesis
by the loss of a single Trp53 allele
To further investigate the mechanisms of NF-κB miss-
regulation imposed by single Trp53 allele loss, we mea-
sured the levels and phosphorylation of IκBα, which is the
main inhibitor of NF-κB signaling49. We detected lower
levels of IκBα in p53 HEM and KO BMDMs compared
with WT cells (Fig. 5A, B), consistent with higher basal
cytokine production in p53 HEM and KO cells. The non-
overlapping IκBα degradation and phosphorylation
kinetics seen after LPS treatment (Fig. 5A) is in agreement
with the oscillation dynamics of NF-kB signaling50. Most
importantly, recovery of IκBα protein levels after LPS-
induced IκBα phosphorylation and subsequent degrada-
tion, which is required for post-activation repression of
NF-κB signaling51,52, was significantly reduced in p53
HEM and KO cells (Fig. 5A, B). However, we detected
comparable levels of P-IκBα in WT, HEM, and KO cells
after LPS treatment (Fig. 5A, C) thus suggesting that
delayed protein recovery in p53 HEM and KO cells was
not due to the increased IκBα degradation but instead of
defective LPS-induced transcription of the Nfkbia gene. In
agreement with this hypothesis, we detected significant
lower Nfkbia levels in p53 HEM and KO BMDM cells
following LPS treatment (Fig. 5D), suggesting that p53
might regulate transcription of the Nfkbia gene, a known
target gene of p65 transcription factor52.
Synergistic effects of p53 and p65 on Nfkbia gene
expression have been previously suggested53. To further
explore the potential mechanism by which p53 tran-
scriptional activity might control NF-κB pathway, we
performed in silico study of the Nfkbia promoter region.
The analysis revealed the presence of binding consensus
sites for p53 as well as p65 (Fig. S5A). p65 ChIP experi-
ments in LPS-treated BMDMs indicated that p53 HEM
and KO cells showed significantly less p65 binding to
Nfkbia promoter (Fig. 5E), which correlates with reduced
LPS-induced IκBα mRNA levels (Fig. 5D). p53 ChIP data
showed that upon LPS stimulation p53 binds the pro-
moter region of Nfkbia in WT and HEM cells (Fig. 5F). As
described54, we did observe p53 binding to the intronic
region of Mdm2 upon UVB (Fig. S5B, C), and as expected,
no p53 binding was detected when using p53 KO cells
(Figs. 5F, S5C).
Overall, these results indicate that p53 influences NF-κB
signaling by transcriptional regulation of the NF-κB
inhibitor IκBα, uncovering a novel crosstalk mechanism
between the p53 and NF-κB transcription factors. Hence,
p53 dosage might impose differential amounts, durations
and patterns of cytokine expression with great impact on
inflammation, oxidative stress, and tumorigenesis.
Increased NF-κB signaling and enhanced expression of
pro-inflammatory cytokines by p53 knockdown
To further demonstrate the impact of Trp53 dosage in
the pro-inflammatory response, p53 expression was
knockdown (KD) in WT BMDM cells by means of shRNA
lentivirus infection. Two shRNA tested against Trp53 (#1
and #2) led to significant decrease in the levels of p53
protein (Fig. 6A, B) and RNA (Fig. 6C) compared to
shRNA scramble. In agreement with the differential
inflammatory response triggered by Trp53 allele loss, the
knockdown of p53 led to an overactivation of NF-κB
pathway after LPS stimulation. Thus, the levels of P-IκBα
were increased in parallel with the decrease in the levels of
total IκBα (Fig. 6D, E) in shRNA Trp53-treated cells
compared with shRNA scramble-treated cells. This effect
was also observed in non-stimulated cells. This basal
activation of NF-κB in KD cells also induce an over-
expression of Nfkbia (Fig. 6F), since this gene is one of the
main NF-κB target52. However, as seen in HEM and KO
cells, the decreased levels of p53 avoid the proper
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expression of Nfkbia after LPS stimulation (Fig. 6G).
Consequently, levels of p53 KD and the overactivation of
NF-κB pathway upon LPS correlated with an enhanced
mRNA expression of the pro-inflammatory cytokines IL-
1α, IL-6, IL-18, and TNFα (Fig. 6H). Although the same
effect was not observed with IL-1β, when the fold change
of expression related to un-stimulated condition is ana-
lyzed, we observed a significant increased expression in
LPS-treated KD BMDMs (Fig. S4B). Therefore, differ-
ences in the expression and kinetics of cytokines might be
related to the different KD efficiency of the two tested
Trp53 shRNA. Overall, these results corroborate that a
Fig. 5 Loss of one Trp53 allele affects NF-κB pathway via regulation of IκBα mRNA expression. A Levels of P-IκBα and IκBα in untreated and
LPS-treated (100 ng/ml) BMDMs from p53 WT, HEM and KO mice at the indicated times. Representative image of a western blot analysis from three
independent experiments is shown. B Quantification of IκBα levels from three independent western blot analysis. A graph for basal levels (left panel)
and a graph for LPS treatment (right panel) are shown. Expression values were referred to tubulin levels. C Quantification of P-IκBα levels from three
independent western blot analysis. Expression values were referred to tubulin levels. D Relative expression of Nfkbia mRNA in BMDMs from WT, HEM
and KO mice treated with LPS (100 ng/ml) at the indicated times. A graph for basal levels (left panel) and a graph for LPS treatment (right panel) are
shown. Values refer to biological replicates in three independent experiments. E p65 ChIP qPCR of Nfkbia promoter. WT, HEM, and KO BMDMs were
untreated and treated with LPS (100 ng/ml, 60 min) before ChIP was performed. Values were normalized to input and the results are shown as fold
change related to control immunoglobulin (Ig) sample. Values refer to biological replicates of two independent experiments. F p53 ChIP qPCR of
Nfkbia promoter. BMDMs were untreated or treated with LPS (100 ng/ml, 60 min) before ChIP was performed. Values are normalized to input and the
results are shown as fold change related to Ig sample. Values refer to biological replicates of three independent experiments for WT and KO, and one
for HEM BMDMs. In B, D, E and F, bars represent mean values ± SEM. In B, C and D (right panels) mean values ± SEM are represented. AU arbitrary
units. Significant differences and p values were derived from an unpaired t-test, two-tailed. wt vs HEM or KO. ****p value < 0.0001, **p value < 0.005,
*p value < 0.05. HEM vs KO. ###p value < 0.0005, #p value < 0.05.
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Fig. 6 p53 knockdown leads to an increased pro-inflammatory cytokine expression and affects NF-κB pathway. WT BMDMs infected with sh
scramble, sh Trp53 #1 or sh Trp53 #2 were untreated and treated with LPS (100 ng/ml) for the indicated times. A p53 protein expression and
B quantification. Representative images of western blot analysis from one experiment are shown. C+, positive control for p53 staining from UVB-
treated cells. Relative expression values were referred to tubulin expression. C Relative mRNA expression of Trp53. Technical replicates were quantified
in one experiment. D P-IκBα and IκBα protein expression and E quantification. Representative image of a western blot analysis from one experiment
is shown. Relative expression values were referred to tubulin expression. F Relative mRNA expression of Nfkbia in untreated BMDMs. Technical
replicates were quantified in one experiment. G Relative mRNA expression of Nfkbia in LPS-treated BMDMs. Technical replicates were quantified in
one experiment. H Relative mRNA expression of the indicated genes. Technical replicates were quantified in one experiment. AU arbitrary units. In
C, F, G and H bars represent mean values ± SEM. Significant differences and p values were derived from an unpaired t-test, two-tailed. Sh scramble vs
sh Trp53 #1 or sh Trp53 #2. ****p value < 0.0001, ***p value < 0.0005, **p value < 0.005, *p value < 0.05.
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decrease in p53 levels, both by single Trp53 allele loss or
p53 KD, drive an increase in the inflammatory response
mediated at least partially by activation of NF-κB pathway.
Discussion
The pivotal role of p53 in maintaining genome integrity
to avoid tumorigenesis has been extensively studied,
including its role in controlling cell cycle, apoptosis, cel-
lular stress and the inflammatory response, among other
functions. Moreover, the importance of p53 dosage in
cancer has become unequivocally evident in mice carrying
supernumerary copies of the Trp53 gene55,56 and in mice
with single or double germline deletion of Trp53 alleles
that show a very different incidence and type of tumors
relative to WT mice15,17–24, as in the present study. In
fact, tumor spectrum and incidence in p53 HEM mice,
rather that KO mice, are more similar to those found in
individuals with Li-Fraumeni syndrome, associated with
germline null or inactivating genetic mutations in a single
allele of the TP53 gene16,57–60. Of note, ~20% of these
patients and 50% of the p53 heterozygous tumors still
retain the wt allele of the gene16,23,61, indicating that p53
haploinsufficiency by loss of one Trp53 allele can be
sufficient to promote carcinogenesis. Nevertheless, the
reasons and mechanisms remain poorly known. In this
context, our work provides novel insights uncovering
manifest differences between mice carrying germline
deletion of one (HEM) or both (KO) Trp53 alleles in
oxidative, DNA damage and inflammatory responses,
well-known triggers of carcinogenesis that, at least in part,
could underlie their distinct tumor phenotype. In this
manner, the single Trp53 allele loss compromises the
maintenance of genomic stability, although to less
extension than the complete loss, mainly in the response
to primary DNA damaging agents (e.g., UVB) rather than
to secondarily induced DNA damage by stress threats
(e.g., LPS)62. Notably, our data also indicate that the loss
of one Trp53 allele directly affects IκBα expression, which
leads to altered NF-κB activation and thereby altered
pattern and levels of pro-inflammatory cytokine expres-
sion, a key non-cell autonomous mechanism that influ-
ences both tumor progression and suppression63.
Relevantly, the differences between single and double
loss of Trp53 alleles in the oxidative status in hemato-
poietic cells and tissues closely parallels the distinct fre-
quency and type of lymphomas reported in p53 HEM and
KO mice. Hence, the low frequency of thymic lymphomas
and predominance of splenic lymphoma in HEM
mice20,21,23 correlates well with the fact that HEM spleen
but not thymus show an increase in oxidative stress
markers. On the other hand, the highest frequency of
lymphomas, especially thymomas, in KO mice20,21,23
parallels with an increased oxidative status in KO thymus
and spleen. Noteworthy, the higher percentage of
CD8+ T cells observed in the p53 KO mice was also
observed in patients with thymomas64. These findings
match with the increased oxidative status reported in
blood and thymus of p53 KO mice9, human cancer cells
upon downregulation of p5365 and, interestingly, blood
and tissue samples from Li-Fraumeni syndrome indivi-
duals66,67. Therefore, mechanisms involved in the main-
tenance of redox homeostasis are among the molecular
basis that can explain the p53 dosage-dependent differ-
ences in tumor spectrum.
In addition, our work reveals that reduced p53 dosage,
resulting from either single and double germinal allele
loss or knockdown, impacts on the oxidative and
inflammatory status by upregulating differently the
expression of key pro-oxidant genes and pro-
inflammatory cytokines in macrophages, in either basal
conditions and after stressor signals. For instance, in
basal conditions, Il6 is upregulated only in p53 KO
BMDMs, whereas Il-23a is upregulated only in HEM
BMDMs. In addition, LPS-induced expression of Il1a
and Il-18 is higher and Il-23 is lower in KO than in HEM
BMDMs. Several evidences indicate that the pattern and
balance of pro-inflammatory cytokines, including IL-1α,
IL-1β, IL-6, IL-12, IL-18, IL-23 and TNF-α, among
others, play a crucial role shaping protumor and anti-
tumor immunity and thereby the development of
tumorigenesis63, as reflected in the differential tumor
phenotype of p53 KO and HEM mice. Increasing evi-
dences highlight p53 as a key player in immunity and
inflammation by regulating directly or indirectly the
expression of numerous key immune genes68,69. The
present results support a role of p53 as repressor of NF-
κB-dependent proinflammatory cytokine induction in
mouse macrophages, which is in agreement with pre-
vious studies in p53-deficient mice9,11,70,71. Intriguingly,
p53 stabilization by nutlin-3 leads also to an increase in
the expression of proinflammatory cytokines72, pointing
to the critical role of the levels of p53 expression in
determining its function. Importantly, our data indicate
that Nfkbia can be a direct target gene for p53 in the
stress inflammatory response, unveiling a novel tran-
scriptional co-activation of IκBα expression by p53 and
p65. To our knowledge, this is the first time to identify a
p53-binding site in the Nfkbia promoter. After stimula-
tion, low or null levels of p53 will impair an efficient p65-
dependent transcriptional re-expression of IκBα, which
is needed to restrain the activation of the NF-κB path-
way51,52. These may represent a new feedback control
mechanism of p53 over NF-κB signaling pathway upon
stress conditions and an additional link in the dense and
complex connection nets taking place between the two
transcription factors. In this context, direct and indirect
mutual regulation73,74 and antagonistic75–77 or coop-
erative53,72,74,78–80 effects between p53 and NF-κB in
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transcriptional regulation depending of the gene, stimuli,
cell type or physiological conditions have been largely
documented.
In sum, the present work provides novel insights in the
mechanisms and consequences of the loss of one Trp53
allele, using p53 HEM mice as a model to study under-
lying pathomechanism of individuals with Li-Fraumeni
syndrome. Single Trp53 allele loss decreases more than
half the amount of p53 protein, triggering an increased
oxidative, DNA damage and inflammatory status by
reducing the expression of IκBα, ultimately leading to
enhanced tumorigenesis. The dependence of p65 on p53
for negative feedback regulation of NF-KB it is of great
interest as it might potentially impact treatment strategies
for patients suffering from autoinflammatory as well as
cancer diseases. Further studies are yet needed to fully
characterize in detail the complex crosstalk mechanisms
between these two relevant transcription factors that link
inflammation and tumorigenesis.
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